Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 1/20 | 0.60 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.60 |
| ▸ | P4HB | P07237 | 14/20 | 0.49 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.46 |
| ▸ | FBP1 | P09467 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6166108 | 1.00 | PDCD1 (0.60) | PDCD1CD274P4HBCYP4F2CYP4A11 | |
| SCHEMBL9514413 | 0.87 | PDCD1 (0.57) | PDCD1CD274P4HBFBP1CYP1A2 | |
| SCHEMBL9514417 | 0.87 | PDCD1 (0.57) | PDCD1CD274P4HBFBP1CYP1A2 | |
| SCHEMBL5970556 | 0.84 | PDCD1 (0.57) | PDCD1CD274P4HBFBP1CYP1A2 | |
| SCHEMBL5970550 | 0.84 | PDCD1 (0.57) | PDCD1CD274P4HBFBP1CYP1A2 | |
| SCHEMBL6163278 | 0.83 | GRIK1 (0.45) | PDCD1CD274P4HBCYP4F2CYP4A11 | |
| SCHEMBL6163281 | 0.83 | GRIK1 (0.45) | PDCD1CD274P4HBCYP4F2CYP4A11 | |
| SCHEMBL6163160 | 0.82 | PDCD1 (0.61) | PDCD1CD274P4HBMAOAMAOB | |
| SCHEMBL16222087 | 0.82 | PDCD1 (0.61) | PDCD1CD274P4HBMAOAMAOB | |
| SCHEMBL11829557 | 0.82 | PDCD1 (0.57) | PDCD1CD274P4HBMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1254136-A4 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG CHEM INVESTMENT LTD (KR) | 2005-06-01 | — | — | EP | disclosed |
| US-20030065176-A1 | Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof | LG CHEM INVESTMENT LTD. (KR) | 2003-04-03 | — | — | US | disclosed |
| EP-1254136-A1 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG Chem Investment, Ltd. (KR) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001055146-A1 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG CHEM INVESTMENT LTD. (KR) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065176-A1 | Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof | F2, F12, TFPI | PDCD1 1905/4885CD274 3646/4885P4HB 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.